Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
86
resultados
Última actualización
01/05/2025 [07:13:00]
Resultados 25 a 50 de 86
Resumen de: AU2023361317A1
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the present invention relates a to a bacterial delivery system and various uses and methods thereof.
Resumen de: WO2023223331A1
The present invention relates to diagnostic platform. More specifically, the invention relates to a dual platform composed of a detection and quantification unit and a characterization unit, systems, kits, methods and uses thereof in detection, quantification and characterization of pathogens, the system comprising monoclonal-antibody-based biosensor chips, for detection and/or quantification of pathogens in a sample, and substrate-based biosensor chips for enzymatically profiling the pathogen in the sample.
Resumen de: KR20250041982A
본 발명은 비장티푸스성 살모넬라 2가 백신의 면역원성 동시 측정용 혈청사멸분석법에 관한 것이다.
Resumen de: AU2022480516A1
Provided is a method against Salmonella typhimurium infection using a composition containing cultures of Lactobacillus rhamnosus LRH10 which is deposited at the Deutsche Sammlung Von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 32786, Lactobacillus paracasei LPC12 which is deposited at the DSMZ GmbH under an accession number DSM 32785, Lactobacillus fermentum LF26 which is deposited at the DSMZ GmbH under an accession number DSM 32784，Streptococcus thermophilus ST30 which is deposited at the DSMZ GmbH under an accession number DSM 32788, and Lactobacillus helveticus LH43 which is deposited at the DSMZ GmbH under an accession number DSM 32787.
Resumen de: AU2023338191A1
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live
Resumen de: US2025093348A1
A nucleic acid testing device and method are provided. A base plate that is turned during nucleic acid testing is included, wherein the base plate includes the following chambers: a sample chamber for adding and containing a nucleic acid sample solution, the nucleic acid sample solution is placed in the chamber, and an upper port of the sample chamber communicates with the outside atmosphere; a reaction chamber for nucleic acid amplification reaction and located below the sample chamber, a nucleic acid amplification reagent for nucleic acid amplification reaction is pre-placed in the chamber, and an upper end of the reaction chamber communicates with a bottom end of the sample chamber though a longitudinal liquid channel; a test strip chamber for lateral flow test strip testing, a nucleic acid test strip is pre-placed in the chamber, and the test strip chamber communicates with the reaction chamber through a bent channel.
Resumen de: US2025092355A1
The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, and engineered host cells for producing fatty acids and derivates of fatty acids such as acyl-CoA, terminal olefins, fatty aldehydes, fatty alcohols, alkanes, alkenes, wax esters, ketones and internal olefins through altered expression of the transcription factor, fadR.
Resumen de: CN119633101A
本发明公开了SseB蛋白在制备交叉免疫同源或异源血清型肠炎沙门菌的疫苗中的应用。本发明使用动物实验评估其免疫保护力，结果发现肠炎沙门菌SseB蛋白具有良好的免疫反应性，可以显著减轻肠炎沙门菌同源或异源血清型野生菌株引起的临床症状。本发明涉及的具有交叉免疫保护作用的肠炎沙门菌SseB蛋白，具有作为研制肠炎沙门菌亚单位疫苗的潜力。
Resumen de: AU2023312737A1
Provided herein are vaccine composition comprising a
Resumen de: US2025084490A1
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
Resumen de: US2025082751A1
The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
Resumen de: WO2025054360A1
The disclosure provides for a vaccine depot formulation that comprises a biodegradable thermosensitive hydrogel that has been loaded or embedded with nanoparticles that comprise an antigen and adjuvant, and uses thereof for protecting a subject from an infection or disease.
Resumen de: US2025074952A1
Provided is a structure for capturing a compound that includes at least one gene or a product thereof, or a combination thereof among a group of genes involved in the intracellular and extracellular transport function of the compound, the gene or the product thereof being multi-componented.
Resumen de: US2025073163A1
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.
Resumen de: KR20250031183A
본 발명은 표적단백질을 효율적으로 분비할 수 있는 살모넬라 균주 및 이의 제조방법에 관한 것으로, fliD 유전자가 불활성화되어, 플라젤린 단백질의 분비가 증가된 변이 살모넬라 균주를, 표적 단백질과 flgM 단백질의 융합단백질을 암호화하는 유전자를 포함하는 유전자 구조물로 형질전환하여, 표적 단백질과 flgM 단백질의 융합단백질 형태로 표적단백질을 분비하는 것을 특징으로 하는 살모넬라 균주 및 이의 제조방법에 관한 것이다.
Resumen de: US2025073282A1
The present invention relates to the technical field of probiotics, in particular to a Lactiplantibacillus plantarum GOLDGUT-LP618 having a function of resisting Salmonella infection and application thereof. The Lactiplantibacillus plantarum GOLDGUT-LP618 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28399. The strain has high resistance to acid and bile salt and can adapt to the digestive tract environment. The strain can inhibit Salmonella infection, relieve diarrhea, inflammation and intestinal damage caused by Salmonella infection, and promote intestinal health. The strain can be used for preparing functional foods, dietary supplements or drugs that can resist Salmonella infection and improve diarrhea and inflammation caused by Salmonella infection, and has good application prospects.
Resumen de: KR20250030119A
본 발명은 신규한 살모넬라 엔테리티디스 온도감수성 변이주에 관한 것으로, 본 발명의 변이 균주는 야생형 균주가 번식하는 닭의 정상 체온인 40 내지 45 ℃에서 성장이 억제되어 집락 형성을 억제하므로, 면역화된 무리 내에서 백신 균주가 장기 순환함으로써 치명적인 복귀 돌연변이체가 될 수 있는 위험성이 없는 충분히 약화된 비병원성 백신 균주이며, 닭에서 살모넬라 엔테리티디스에 대항하여 충분한 안전성, 방어 효능 및 면역 반응을 나타냈고, 그에 일치한 표현형 및 유전형 변화도 보였으므로, 이를 온도감수성(온도민감성) 약독화 생균 백신의 유효성분으로 유용하게 사용할 수 있다.
Resumen de: JP2023175686A
To provide compositions for use in enhancing human immune response and/or as adjuvants in vaccines.SOLUTION: A composition includes an antigen and a specific imidazopyrimidine compound.SELECTED DRAWING: None
Resumen de: AU2023262222A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Resumen de: JP2024012307A
To provide modified or mutant forms of secretin and compositions comprising the same, and methods for using modified or mutant forms of secretin and compositions for characterizing an analyte, e.g., a target polynucleotide.SOLUTION: The disclosure provides analyte detection using a modified secretin as a nanopore. The disclosure provides a modified secretin nanopore disposed in a membrane, wherein the modified secretin nanopore comprises a lumenal surface defining a lumen that extends through the membrane between a cis-opening and a trans-opening, wherein the lumenal surface comprises one or more amino acid modifications.SELECTED DRAWING: None
Resumen de: WO2025042889A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.
Resumen de: US2025064866A1
The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
Resumen de: US2025064910A1
Technologies for the prevention and/or treatment of Salmonella infections.
Resumen de: US2025066429A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Nº publicación: WO2025039454A1 27/02/2025
Solicitante:
MINSHENG ZHONGKE JIAYI ZHEJIANG BIOENGINEERING CO LTD [CN]
HANGZHOU MINSHENG HEALTHCARE CO LTD [CN]
\u6C11\u751F\u4E2D\u79D1\u5609\u4EBF\uFF08\u6D59\u6C5F\uFF09\u751F\u7269\u5DE5\u7A0B\u6709\u9650\u516C\u53F8,
\u676D\u5DDE\u6C11\u751F\u5065\u5EB7\u836F\u4E1A\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: WO2025039454A1
A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric/intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.
BOPI
Sede Electrónica
